PMV Pharmaceuticals to Participate in the Guggenheim Healthcare Talks 2022 Oncology Day
February 03, 2022 08:00 ET
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., Feb. 03, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
PMV Pharma Announces Changes to its Board of Directors
January 06, 2022 08:00 ET
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
PMV Pharma to Present at the Evercore ISI 4th Annual HealthCONx Conference
November 22, 2021 08:00 ET
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
PMV Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highlights
November 12, 2021 07:15 ET
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., Nov. 12, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a clinical-stage oncology company pioneering the discovery and development of small molecule therapies...
PMV Pharmaceuticals Appoints Tim Smith as Senior Vice President, Head of Corporate Development
September 09, 2021 08:00 ET
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., Sept. 09, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
PMV Pharmaceuticals to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
September 02, 2021 08:00 ET
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., Sept. 02, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
PMV Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights
August 13, 2021 08:00 ET
|
PMV Pharmaceuticals, Inc.
Continued enrollment in Phase 1/2 trial of first-in-class p53 Y220C reactivator PC14586 CRANBURY, N.J., Aug. 13, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a...
PMV Pharmaceuticals Announces Participation at the Bank of America Securities 2021 Napa Biopharma Virtual Conference
June 09, 2021 08:00 ET
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., June 09, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
PMV Pharmaceuticals Announces Participation at the Goldman Sachs Annual Healthcare Conference
June 03, 2021 08:00 ET
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., June 03, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
PMV Pharmaceuticals Reports First Quarter 2021 Financial Results and Corporate Highlights
May 14, 2021 08:00 ET
|
PMV Pharmaceuticals, Inc.
Presented late breaking preclinical data on PC14586, the Company’s first-in-class, tumor-agnostic, investigational small molecule p53 Y220C reactivator at the American Association for Cancer Research...